EMERGENT BIOSOLUTIONS INC. Operating Lease, Lease Income, Lease Payments
EMERGENT BIOSOLUTIONS INC. (EBS) reported Operating Lease, Lease Income, Lease Payments of $5.70 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Income Statement › Other Income
us-gaap:OperatingLeaseLeaseIncomeLeasePayments · last filed 2024-03-08
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income, lease payments for fiscal 2023 was $5.70M, a 16.33% increase from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. operating lease, lease income, lease payments for fiscal 2022 was $4.90M.
| Period end | Operating Lease, Lease Income, Lease Payments 12 month |
|---|---|
| 2023-12-31 | $5.70M 10-K · filed 2024-03-08 |
| 2022-12-31 | $4.90M 10-K/A · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |